123 results

• Double-blind

  A study design where neither participants nor researchers know which treatment each participant receives, reducing the likelihood of bias in the results.

  Reference:

  Harvard Health. Medical dictionary of health terms: D through I [Internet]. [cited 2025 Nov]. Available from: https://www.health.harvard.edu/d-through-i

• Dysarthria

  A speech disorder of neurological origin marked by impaired articulation.

  Reference:

  ScienceDirect Topics. Dysarthria [Internet]. [cited 2025 Nov]. Available from: https://www.sciencedirect.com/topics/neuroscience/dysarthria

• Dysgeusia

  An alteration or distortion in the normal sense of taste.

  Reference:

  ScienceDirect Topics. Dysgeusia [Internet]. [cited 2025 Nov]. Available from: https://www.sciencedirect.com/topics/nursing-and-health-professions/dysgeusia

• Dysphagia

  Difficulty swallowing that often requires changes in diet. Some individuals with dysphagia struggle with certain foods or liquids, while others are unable to swallow at all. Additional signs may include coughing or choking during meals, regurgitating food, feeling as though food is stuck in the throat or chest, and continuous drooling.

  Reference:

  NHS inform. Dysphagia (swallowing problems) [Internet]. [cited 2025 Nov]. Available from: https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/dysphagia-swallowing-problems/

• Economic burden

  In the medical context refers to the total financial impact that a disease or health condition imposes on individuals, households, healthcare systems, and society. This burden is typically divided into direct costs (such as expenditures for medical care, hospitalizations, medications, diagnostic tests, and preventive actions) and indirect costs (including lost productivity, absenteeism, presenteeism, loss of income, and premature death).

  Reference:

  LaVeist TA, Pérez-Stable EJ, Richard P, et al. The economic burden of racial, ethnic, and educational health inequities in the US. JAMA. 2023;329(19):1682-1692. doi:10.1001/jama.2023.5965

• Efficacy

  The ability of an intervention to produce the intended effect under controlled study conditions.)

  Reference:

  EU Clinical Trials Register. Glossary [Internet]. [cited 2025 Nov]. Available from: https://www.clinicaltrialsregister.eu/doc/EU_Clinical_Trials_Register_Glossary.pdf

• Endpoint

  A predefined variable or outcome used to evaluate the effect, safety, or other impact of a treatment or intervention. For example, the primary efficacy endpoint in PROSPER is the change from baseline to Week 52 on the PSP Rating Scale (PSPRS).

  Reference:

  EU Clinical Trials Register. Glossary [Internet]. [cited 2025 Nov]. Available from: https://www.clinicaltrialsregister.eu/doc/EU_Clinical_Trials_Register_Glossary.pdf | ClinicalTrials.gov. PROSPER (NCT06355531) [Internet]. [cited 2025 Nov]. Available from: https://clinicaltrials.gov/study/NCT06355531

• Epigenetic

  Refers to heritable changes that do not affect the DNA sequence but influence gene expression (e.g., chemical modifications).

  Reference:

  ScienceDirect Topics. Epigenetics [Internet]. [cited 2025 Nov]. Available from: https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/epigenetics

• Extracellular

  Located or occurring outside the cell.

  Reference:

  ScienceDirect Topics. Extracellular space [Internet]. [cited 2025 Nov]. Available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/extracellular-space

• Eyelid opening apraxia

  Inability to voluntarily open the eyelids after they have been closed for a period of time.

  Reference:

  Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853-864. doi:10.1002/mds.26987

• Familial PSP

  Cases of PSP that occur in multiple members of the same family, suggesting a hereditary component.

  Reference:

  Donker Kaat L, Boon AJ, Azmani A, et al. Familial aggregation of parkinsonism in progressive supranuclear palsy. Neurology. 2009;73(2):98-105. doi:10.1212/WNL.0b013e3181a92bcc

• FNP-223

  Investigational, brain-penetrant, selective OGA inhibitor intended as a potential DMT for PSP.

  Reference:

  Permanne B, Sand A, Ousson S, et al. O-GlcNAcase inhibitor ASN90 is a multimodal drug candidate for tau and α-synuclein proteinopathies. ACS Chem Neurosci. 2022;13(8):1296-1314. doi:10.1021/acschemneuro.2c00057

• Frontal cognitive/behavioral presentation

  Defined as at least three of the following features, which have to be persistent: apathy; bradyphenia; dysexecutive syndrome; reduced phonemic verbal fluency; impulsivity, disinhibition, or perseveration.

  Reference:

  Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853-864. doi:10.1002/mds.26987

• Frontal dysfunction

  Impairment of the frontal lobe, which affects executive, cognitive, or behavioral functions.

  Reference:

  Pirau L, Lui F. Frontal lobe syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532981/

• Gait freezing

  Sudden and transient inability to initiate walking, often described as the feet being “glued” to the floor.

  Reference:

  Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853-864. doi:10.1002/mds.26987